Date:9/30/2010

n (150,407) (1,301,337) Taxes payable (5,028,760) 11,081,110 Net cash provided by operating activities 20,255,834 62,924,266 CASH FLOWS FROM INVESTING ACTIVITIES: Acquisition of Hongrui -- (8,584,900) Proceeds from sale of investments 531,750 407,005 Purchase of equipment (76,993) (156,702) Prepayments made for purchase of equipment (110,251) -- Purchase of intangible assets (16,979,106) -- Cash proceeds from sale of equipment -- 15,615 Net cash used in investing activities (16,634,600) (8,318,982) CASH FLOWS FROM FINANCING ACTIVITIES: Change in restricted cash (3,754,752) 538,815 Proceeds from notes payable 14,843,004 13,896,990 Principal payments on notes payable (11,088,252) (12,439,315) Borrowings on short term bank loans 2,200,050 2,197,500 Principal payments on short term bank loans (2,200,050) (2,783,500) Net cash provided (used) in financing activities -- 1,410,490 EFFECTS OF EXCHANGE RATE CHANGE IN CASH 629,384 154,545 NET INCREASE IN CASH 4,250,618 56,170,319 CASH, beginning of the period 104,366,117 48,195,798 CASH, end of the period $108,616,735 $104,366,117 SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION: Cash paid for interest $142,523 $2,255,809 Cash paid for taxes $14,900,838 $6,167,810 Non-cash investing and financing activities: Common stock issued to acquire Hongrui $-- 2,597,132 JIANGBO PHARMACEUTICALS, INC. AND SUBSIDIARIES (FORMERLY GENESIS PHARMACEUTICALS ENTERPRISES, INC.) RECONCILIATION OF NON-GAAP NET INCOME (Unaudited) For the Three Months For the Twelve Months Ended Ended June 30, June 30, 2010 2009 2010 2009 Net Income $7,186,273 $11,491,718 $29,850,355 $28,880,264 Loss from discontinued operations 43,023 88,116 243,792 1,781,946 Unrealized loss (gain) on investments 119,814 (1,026,097) (150,525) 229,425 Loss (gain) in fair value of derivative liabilities (1,141,384) -- (14,631,455) -- Amortization of debt discount and debt issuance costs related to convertible debentures 3,543,451 1,497,392 15,624,371 4,687,144 Adjusted Net Income $9,
'/>"/>

SOURCE Jiangbo Pharmaceuticals, Inc. Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18
Related medicine technology :

1. Jiangbo Pharmaceuticals Chairman to Ring NASDAQ Opening Bell on August 27, 2010
2. Jiangbo Pharmaceuticals Announces the Commercial Launch of Felodipine Sustained Release Tablets
3. Jiangbo Pharmaceuticals to Attend Global Hunter Securities China Conference
4. Jiangbo Pharmaceuticals Announces the Appointment of New Chief Executive Officer
5. Jiangbo Pharmaceuticals, Inc. Receives Approval to List on the NASDAQ Global Market
6. Jiangbo Pharmaceuticals Reports Results for Third Quarter of Fiscal Year 2010
7. Jiangbo Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2010
8. Jiangbo Pharmaceuticals Announces Conference Call to Discuss Results for Its Second Quarter of Fiscal Year 2010
9. Jiangbo Pharmaceuticals Osteomyelitis Treatment Tablets to be Included in Chinas National Insurance Directory
10. Jiangbo Pharmaceuticals Obtains Renewal of GMP Certificate
11. Jiangbo Pharmaceuticals Announces First Quarter Fiscal Year 2010 Results